Insmed Incorporated (NASDAQ:INSM) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC lowered its position in Insmed Incorporated (NASDAQ:INSMGet Rating) by 21.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,905 shares of the biopharmaceutical company’s stock after selling 810 shares during the period. Nisa Investment Advisors LLC’s holdings in Insmed were worth $68,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in INSM. Assenagon Asset Management S.A. lifted its position in Insmed by 8,961.3% in the first quarter. Assenagon Asset Management S.A. now owns 803,734 shares of the biopharmaceutical company’s stock valued at $18,888,000 after purchasing an additional 794,864 shares during the period. Alliancebernstein L.P. lifted its position in Insmed by 27.2% in the fourth quarter. Alliancebernstein L.P. now owns 2,819,013 shares of the biopharmaceutical company’s stock valued at $76,790,000 after purchasing an additional 603,211 shares during the period. Dimensional Fund Advisors LP lifted its position in Insmed by 254.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 409,216 shares of the biopharmaceutical company’s stock valued at $11,147,000 after purchasing an additional 293,890 shares during the period. Alps Advisors Inc. acquired a new stake in Insmed in the fourth quarter valued at about $3,732,000. Finally, Bellevue Group AG lifted its position in Insmed by 4.0% in the fourth quarter. Bellevue Group AG now owns 3,520,861 shares of the biopharmaceutical company’s stock valued at $95,908,000 after purchasing an additional 135,216 shares during the period.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on INSM shares. The Goldman Sachs Group reduced their price objective on shares of Insmed from $56.00 to $48.00 and set a “buy” rating for the company in a research report on Tuesday, May 24th. Morgan Stanley dropped their target price on shares of Insmed from $46.00 to $41.00 and set an “overweight” rating for the company in a report on Friday, July 15th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $49.67.

Insider Transactions at Insmed

In other news, CEO William Lewis sold 96,614 shares of the firm’s stock in a transaction that occurred on Thursday, July 7th. The shares were sold at an average price of $23.00, for a total transaction of $2,222,122.00. Following the completion of the transaction, the chief executive officer now directly owns 256,716 shares of the company’s stock, valued at approximately $5,904,468. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, Director Melvin Md Sharoky bought 20,000 shares of the stock in a transaction on Wednesday, May 11th. The stock was purchased at an average cost of $17.20 per share, with a total value of $344,000.00. Following the purchase, the director now owns 262,621 shares of the company’s stock, valued at $4,517,081.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO William Lewis sold 96,614 shares of Insmed stock in a transaction that occurred on Thursday, July 7th. The stock was sold at an average price of $23.00, for a total transaction of $2,222,122.00. Following the completion of the sale, the chief executive officer now directly owns 256,716 shares of the company’s stock, valued at $5,904,468. The disclosure for this sale can be found here. Corporate insiders own 4.40% of the company’s stock.

Insmed Trading Down 1.8 %

Shares of Insmed stock opened at $22.12 on Friday. The company has a current ratio of 6.04, a quick ratio of 5.52 and a debt-to-equity ratio of 6.73. The company has a 50-day moving average of $20.63 and a two-hundred day moving average of $21.98. Insmed Incorporated has a 12-month low of $16.41 and a 12-month high of $34.44. The stock has a market cap of $2.64 billion, a PE ratio of -5.85 and a beta of 1.93.

Insmed (NASDAQ:INSMGet Rating) last issued its quarterly earnings data on Thursday, May 5th. The biopharmaceutical company reported ($0.80) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.91) by $0.11. Insmed had a negative net margin of 217.35% and a negative return on equity of 108.20%. The business had revenue of $53.10 million during the quarter, compared to analysts’ expectations of $53.36 million. During the same period last year, the company posted ($0.89) EPS. The company’s revenue was up 32.1% on a year-over-year basis. On average, research analysts anticipate that Insmed Incorporated will post -3.52 EPS for the current fiscal year.

Insmed Profile

(Get Rating)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

See Also

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSMGet Rating).

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.